NCT00788528View on ClinicalTrials.gov

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

766

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2010

Conditions
Obesity
Interventions
DRUG

S-2367 (velneperit)

Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks

Trial Locations (73)

13104

Manlius

13760

Endwell

14609

Rochester

19020

Bensalem

23294

Richmond

27103

Winston-Salem

27215

Burlington

27612

Raleigh

28025

Concord

28144

Salisbury

29464

Mt. Pleasant

29615

Greenville

30328

Atlanta

30338

Atlanta

30909

Augusta

32216

Jacksonville

32259

Jacksonville

32809

Orlando

33134

Coral Gables

34471

Ocala

34996

Stuart

35209

Birmingham

35801

Huntsville

36608

Mobile

37029

Burns

37203

Nashville

37620

Bristol

37920

Knoxville

39501

Gulfport

40509

Lexington

43212

Columbus

44122

Cleveland

44260

Mogadore

45219

Cincinnati

47714

Evansville

53226

Wauwatosa

54303

Green Bay

55430

Brooklyn Center

60031

Gurnee

60607

Chicago

60654

Chicago

62704

Springfield

63141

St Louis

64114

Kansas City

66218

Shawnee Mission

67207

Wichita

68134

Omaha

68510

Lincoln

71913

Hot Springs

73099

Yukon

77024

Houston

77566

Jackson

78130

New Braunfels

78229

San Antonio

83704

Boise

84088

West Jordan

85014

Phoenix

85701

Tucson

89146

Las Vegas

92108

San Diego

92708

Fountain Valley

94102

San Francisco

95608

Carmichael

95816

Sacramento

98057

Renton

06905

Stamford

06708

Waterbury

02135

Boston

01757

Milford

02747

South Dartmouth

08009

Berlin

08817

Edison

02920

Cranston

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY

NCT00788528 - Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects | Biotech Hunter | Biotech Hunter